JP Morgan Chase’s BioNexus Gene Lab BGLC Stock Holding History

JP Morgan Chase’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-58	Closed	-$162	–	7342
2024 Q4	$162	Buy	+58	New	+$191	﹤0.01%	6939

Other funds holding BGLC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase's BGLC Position: Q1 2025 in Review

JP Morgan Chase sold out of BioNexus Gene Lab (BGLC) in Q1 2025, closing a stake of 58 shares — an estimated $162 sold.

JP Morgan Chase first reported a position in BGLC in Q4 2024 and held it in 1 quarter. The position peaked at $162 in Q4 2024. 3 funds tracked by Wall St. Rank hold BGLC as of Q1 2025.

JP Morgan Chase reported no remaining BioNexus Gene Lab position as of Q1 2025 after selling out during the quarter.
JP Morgan Chase sold 58 BioNexus Gene Lab shares in Q1 2025, an estimated $162.
JP Morgan Chase first reported a position in BioNexus Gene Lab in Q4 2024 and held it in 1 quarter.
JP Morgan Chase's BioNexus Gene Lab position peaked at $162 in Q4 2024.
3 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.